Physician profile
Hemant C Modi
NPI 1033186267
$927.08
in general payments reported to CMS, 2019-2025
13 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $25.95 · 2021: $104 · 2023: $153 · 2024: $201 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $254.52 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.05 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.63 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $116.72 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $63.16 | 2019-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $57.15 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $44.76 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $29.61 | 2023 | Verquvo |
| Pfizer INC. | $25.61 | 2023 | |
| Bridgebio Pharma, INC. | $24.69 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $19.89 | 2025 | Onpattro |
| Amarin Pharma, INC. | $13.71 | 2019 | |
| Amgen INC. | $12.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemant Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.